120 related articles for article (PubMed ID: 2956111)
1. Effect of medroxyprogesterone acetate, alone or in combination with epirubicin hydrochloride, on the growth of the Dunning R3327H prostatic adenocarcinoma.
Landström M; Tomić R; Damber JE
Eur Urol; 1987; 13(3):203-6. PubMed ID: 2956111
[TBL] [Abstract][Full Text] [Related]
2. Treatment of rat prostatic adenocarcinoma with medroxyprogesterone acetate (MPA): effects on growth and morphology.
Damber JE; Bergh A; Landström M; Tomić R
J Urol; 1991 Jun; 145(6):1283-7. PubMed ID: 1827847
[TBL] [Abstract][Full Text] [Related]
3. Experiences with doxo/epirubicin and medroxyprogesterone acetate (MPA) in prostatic cancer.
Anderström C
Cancer Chemother Pharmacol; 1994; 35 Suppl():S97-100. PubMed ID: 7994797
[TBL] [Abstract][Full Text] [Related]
4. Direct effects of oestradiol on growth and morphology of the Dunning R3327H prostatic carcinoma.
Daehlin L; Bergh A; Damber JE
Urol Res; 1987; 15(3):169-72. PubMed ID: 3629752
[TBL] [Abstract][Full Text] [Related]
5. Blood flow in the Dunning R3327H rat prostatic adenocarcinoma; effects of oestradiol and testosterone.
Daehlin L; Damber JE
Urol Res; 1986; 14(2):113-7. PubMed ID: 3727214
[TBL] [Abstract][Full Text] [Related]
6. Antiestrogens do not counteract the inhibitory effect of estradiol-17 beta on the growth of the Dunning R3327 prostatic adenocarcinoma.
Landström M; Damber JE; Bergh A; Tomic R; Carlsson-Bostedt L; Stigbrand T
Prostate; 1988; 12(4):287-98. PubMed ID: 3393491
[TBL] [Abstract][Full Text] [Related]
7. Role of prolactin in modulating the effects of tamoxifen on growth of the Dunning R3327 rat prostate adenocarcinoma.
Sylvester PW; Ip MM
Prostate; 1987; 10(1):57-67. PubMed ID: 3822918
[TBL] [Abstract][Full Text] [Related]
8. Hormonal and chemotherapeutic treatment of prostatic carcinoma; Dunning adenocarcinoma of the prostate in Copenhagen-Fischer rats.
Rosenberg CA; Hrushesky WJ; Langevin T; Kennedy BJ
Oncology; 1985; 42(1):48-54. PubMed ID: 3969257
[TBL] [Abstract][Full Text] [Related]
9. A trial of combination chemotherapy followed by hormonal therapy for previously untreated metastatic carcinoma of the prostate.
Seifter EJ; Bunn PA; Cohen MH; Makuch RW; Dunnick NR; Javadpour N; Bensimon H; Eddy JL; Minna JD; Ihde DC
J Clin Oncol; 1986 Sep; 4(9):1365-73. PubMed ID: 2943877
[TBL] [Abstract][Full Text] [Related]
10. Antitumoral effects of R 75251 on the growth of transplantable R3327 prostatic adenocarcinoma in rats.
Van Ginckel R; De Coster R; Wouters W; Vanherck W; van der Veer R; Goeminne N; Jagers E; Van Cauteren H; Wouters L; Distelmans W
Prostate; 1990; 16(4):313-23. PubMed ID: 2371176
[TBL] [Abstract][Full Text] [Related]
11. Experimental treatment of prostatic cancer by intermittent hormonal therapy.
Trachtenberg J
J Urol; 1987 Apr; 137(4):785-8. PubMed ID: 3560348
[TBL] [Abstract][Full Text] [Related]
12. A randomized study on hormone-resistant prostatic cancer: estramustine phosphate versus low dose epirubicin with or without medroxyprogesterone acetate. A Norwegian multicenter study.
Tveter KJ; Hagen S; Holme I; Klepp O; Kloster SE; Muri O; Poulsen C; Sander S; Sivertsen S; Urnes T
Scand J Urol Nephrol; 1990; 24(4):243-7. PubMed ID: 2148830
[TBL] [Abstract][Full Text] [Related]
13. [Combination with medroxyprogesterone acetate and chemotherapy making possible complete removal of uterine corpus carcinoma].
Tajima H; Okada T; Fujimori Y; Tomioka Y; Hirano M; Yoshida T; Ikeda S; Hata T
Gan To Kagaku Ryoho; 1989 Jul; 16(7):2461-4. PubMed ID: 2526620
[TBL] [Abstract][Full Text] [Related]
14. Effect of medroxyprogesterone acetate on the growth of mouse transplanted tumors: relation with hormone sensitivity.
Formelli F; Ronchi E; Di Fronzo G
Anticancer Res; 1985; 5(3):313-9. PubMed ID: 3160299
[TBL] [Abstract][Full Text] [Related]
15. Sequentially alternating hormone chemotherapy with high-dose medroxy-progesterone acetate and low-dose epirubicin for the treatment of hormone-resistant metastatic prostatic cancer.
Kontturi M; Sotarauta M; Tammela T; Lukkarinen O; Romppainen ML; Gröhn P
Eur Urol; 1988; 15(1-2):43-7. PubMed ID: 2975221
[TBL] [Abstract][Full Text] [Related]
16. Epirubicin and medroxyprogesterone acetate versus estramustine phosphate in hormone-resistant prostatic cancer: a prospective randomized study.
Anderström C; Eddeland A; Folmerz P; Hansson R; Milles S; Zachrisson B
Eur Urol; 1995; 27(4):301-5. PubMed ID: 7656906
[TBL] [Abstract][Full Text] [Related]
17. Sequential alternating medroxyprogesterone acetate and epirubicin in the treatment of advanced breast cancer.
Smith JA; Green MD; Russell IS; Collins JP
Aust N Z J Surg; 1989 Nov; 59(11):869-72. PubMed ID: 2530970
[TBL] [Abstract][Full Text] [Related]
18. [Combination effect of flutamide and leuprorelin acetate on growth of Dunning R3327-H prostatic adenocarcinoma in rats].
Tomura A; Kuroiwa S; Okada M; Abe F
Gan To Kagaku Ryoho; 1998 Mar; 25(4):563-9. PubMed ID: 9530363
[TBL] [Abstract][Full Text] [Related]
19. Treatment of stage D2 prostatic cancer refractory to or relapsed following castration plus oestrogens. Comparison of aminoglutethimide plus hydrocortisone with medroxyprogesterone acetate plus hydrocortisone.
Bezwoda WR
Br J Urol; 1990 Aug; 66(2):196-201. PubMed ID: 2143960
[TBL] [Abstract][Full Text] [Related]
20. Effects of 6-methylene progesterone on growth, morphology, and blood flow of the Dunning R3327 prostatic adenocarcinoma.
Damber JE; Bergh A; Daehlin L; Petrow V; Landström M
Prostate; 1992; 20(3):187-97. PubMed ID: 1574466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
